What is Ionetix?
Ionetix operates at the intersection of advanced physics and clinical healthcare, specializing in the development and operation of compact superconducting cyclotrons. By facilitating the on-site and distributed production of medical radioisotopes, the company addresses critical supply chain vulnerabilities in the healthcare sector. Its core offerings include PET tracers and therapeutic alpha emitters, which are essential for modern oncology and diagnostic imaging. By decentralizing the production of these high-value agents, Ionetix enables healthcare providers to maintain consistent access to life-saving radiopharmaceuticals, thereby improving patient outcomes and operational efficiency in clinical settings.
How much funding has Ionetix raised?
Ionetix has raised a total of $31M across 2 funding rounds:
Debt
$1M
Stock/Share Issuance
$30M
Debt (2020): $1M with participation from PPP
Stock/Share Issuance (2026): $30M, investors not publicly disclosed
Key Investors in Ionetix
Undisclosed Investor
An undisclosed institutional investor participating in the latest funding round to support Ionetix's strategic expansion.
PPP
Public-Private Partnership
What's next for Ionetix?
With this major enterprise-level funding, Ionetix is well-positioned to accelerate its infrastructure deployment and expand its footprint in the radiopharmaceutical market. The strategic roadmap likely involves scaling the manufacturing capacity of its superconducting cyclotrons and deepening its integration into hospital networks. As the demand for targeted radiopharmaceuticals continues to rise, the company's ability to provide reliable, localized production will be a key differentiator. Future growth will likely focus on enhancing the throughput of its alpha emitter production lines and securing further partnerships with major healthcare systems to solidify its market leadership in the precision medicine ecosystem.
See full Ionetix company page
